Tango Therapeutics

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the bottom line, with a Diluted GAAP EPS loss of $0.37 vs. the -$0.32 expected. Revenue was $0.0M, in-line with expectations as collaboration income with Gilead concluded in 2025. The net loss of $55.3M was wider than the $47.2M consensus, driven primarily by elevated R&D spend for the vopimetostat and TNG456 clinical programs, alongside a sharp increase in G&A personnel costs. Despite the earnings miss, the company significantly strengthened its balance sheet via a $651.4M net proceed equity offering, extending its cash runway with $1.0B in liquidity.